Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.

Annals of laboratory medicine - 1 Nov 2012

Ha Jung-Sook, Kim Yu-Kyung, Jung Soon-Il, Jung He-Ra, Chung In-Sung

Abstract excerpt

BACKGROUND: This study evaluated potential correlations between the allele burden of the Janus kinase 2 (JAK2) V617F mutation and clinicohematologic characteristics in patients with myeloproliferative neoplasms (MPN). METHODS: Clinical and hematologic features were reviewed for 103 MPN patients, including patients with polycythemia vera (PV, 22 patients), essential thrombocythemia (ET, 64 patients), and primary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hematocrit
Share to Hemoglobins
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukocyte Count

Share to Myeloproliferative Disorders

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Thrombocythemia, Essential

Source

Open in PubMed Open full text

Identifiers

PMID: 23130336
DOI: 10.3343/alm.2012.32.6.385
PMCID: PMC3486931

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.PMID 23130336Read ↗

High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.Semantic proximity Read ↗

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burdenSemantic proximity Read ↗

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.Semantic proximity Read ↗

Janus kinase mutations.Semantic proximity Read ↗

JAK2 V617F Mutational Burden and Clinical Findings Relationship in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.Semantic proximity Read ↗

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F EraSemantic proximity Read ↗

Myeloproliferative neoplasms and JAK2 mutations.Semantic proximity Read ↗

Relationship of JAK2 (V617F) Allelic Burden with Clinico- Haematological Manifestations of Philadelphia-Negative Myeloproliferative Neoplasms.Semantic proximity Read ↗

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.Semantic proximity Read ↗

JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.